Sinobiopharma, Inc. (fka SNBP)

[pappy]

SNBP filed after the market closed. 2010 eps $0.03 vs-$0.03 in 2009 meeting management guidance.

Revenue doubled almost entirely from their flagship product.

margin improvement due to increased revenue from the flagship product helped the bottomline while increased sharecount did not.

However some debt was extingished & the balance sheet showed marked improvement.

It will be interesting to see how much newer products contribute to revenue in the upcoming 1st qtr 2011 results ending August 31.

They still have a strong pipeline of products in development that need additional funding.